Sentinel Lymph Node Biopsy in the Breast Carcinoma in Clinical Practice
Authors:
J. Gatěk 1; L. Hnátek 1; B. Dudešek 1; P. Vážan 3; J. Bakala 2; K. Hradská 1; J. Kotoč 1; T. Musil 1; J. Duben 1
Authors‘ workplace:
Chirurgické oddělení Nemocnice Atlas a. s. Zlín, Univerzita Tomáše Bati ve Zlíně, vedoucí:
prim. MUDr. J. Gatěk Ph. D.
1; Oddělení nukleární medicíny Krajská nemocnice Tomáše Bati a. s. Zlín, vedoucí: prim. MUDr. J. Bakala
2; Bioptická a cytologická laboratoř Zlín, vedoucí: MUDr. J. Velecký
3
Published in:
Rozhl. Chir., 2008, roč. 87, č. 4, s. 180-185.
Category:
Monothematic special - Original
Overview
Aim:
In the management of early breast carcinoma, biopsy of sentinel lymph nodes has gradually replaced dissection of Level I and II axillary nodes. The aim of the study is to assess feasability and reliability of the method in our conditions.
Method:
From June 1998 to June 2007, a total of 458 sentinel node biopsies (SLNB) were performed. Originally, patent blue sentinel node mapping was used. Since 2000, a combination of radiocolloid application and a gamma- probe (detector), as well as the patent blue, has been used. Originally, SLNBs were followed by axillary dissections, however, in 2002, the procedure was waived in cases of negative sentinel nodes findings.
Results:
Out of the total of 458 SLNB patients, 382 female patients were included in the study. SLNB, without concomitant axillary dissection, was performed in 170 subjects. In 70 subjects, the sentinel node was positive and they were indicated for axillary dissections. Positive non-sentinel nodes were detected 17 times. In total, 899 sentinel nodes were examined in the study group of 382 biopsies. The mean was 2.35. False negative nodes were recorded in three cases in female patients with SLNB and axillary dissection (4.6%). No local relapses in the axilla were recorded in negative sentinel node findings without subsequent axillary dissections.
Conclusion:
Sentinel node biopsy is a safe alternative to axillary dissection in the surgical management of early breast carcinoma.
Key words:
breast carcinoma – sentinel lymph node – axillary dissection
Sources
1. Morton, D., Wen, D., Wong, J., Cagle, L., Storm, K., Foshyg, L., Cochran, A. Technical Details of Intraoperative Lymphatic Mapping for Early Stage Melanoma. Arch. Surg., 1992, 127, 292–299.
2. Krag, D., Weaver, D., Alex, J., et al. Surgical Resection and Radiolocalization of the Sentinel Lymph Node in Breast Cancer Using a Gamma Probe. Surg. Oncol., 1993, 2, 335–340.
3. Giulliano, A., Dale, P., Turner, R., Morton, D., et al. Improved Axillary Staging of Breast Cancer wiťh Sentinel Lymphadenectomy Ann. Surg., 1995, 222, 394–401.
4. Turner, R., Ollila, D., Krasne, D, Giuliano, A. Histopathologic Validation of the Sentinel Lymph node Hypothesis for Breast Carcinoma. Ann. Surg., 1997, 226, 271–278.
5. Veronesi, U., Paganeli, G., Galimberti, V., et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet, 1997, 349, 1864–1867.
6. Naik, A., Fey, J., Cody, H. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection a follow up study of 4808 procedures. Ann. Surg., 2004, 240, 462–471.
7. Veronesi, U., Paganelli G., Viale, G., et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N. Engl. Med., 2003, 349, 546–553.
8. Schwartz, G., Giuliano, A., Veronesi, U., et al. Preceedings of the Consensus Conference on the Role of Sentinel Lymph Node Biopsy in Carcinoma of the Breast April 19-22, 2001 Philadelphia Pennsylvania. Cancer, 2002. 94. 2542–2551.
9. Kühn, Bembenek, A., Buchels, H., et al. Interdisciplinare abgestimmter Konsensus der deutschen Gesellschaft fur Senologie fur eine qualiätsgesicherte Anwendung in der klinischen Routine. Onkologe, 2003, 9, 1011–1016.
10. Zee, K., Manasseh, D., Bevilacquam, J. A nomogram for predicting the likelihood o additional nodal meastases in breast cancer patients with a positive sentinel node biopsy. Ann. Surg. Oncol., 2003, 10, 1140–1151.
11. Xing, Y., Foy, M., Cox, D., et al. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br. J. Surg., 2006, 93, 539–546.
12. Houvenaeghel, G., Nos, C., Mignotte, H., et al. Micrometastases in Sentinel Lymph Node in a Multicentric Study: Predictive Factors of Nonsentinel Lymph Node Involvement -Groupe Des Chirurgiens De La Federation Des Centres De Lutte Contre Le Cancer. J. Clin. Oncol., 2006, 24, 1814–1822.
13. Yeung, H., Cody, H., Turlakow, A., et al. Lymphoscintigraphy and Sentinel Node Localization in Breast Cancer Patiens: A Comparison Bettwen 1-Day and 2-Day protocols. J. Nucl. Med., 2001, 42, 420–423.
14. Duff, M., Hill, A., Greal, G., Walsh, S., et al. Prospective evaluation of the morbidity of axillary clearence for breast cancer. Br. J. Surg., 2001, 88, 114–117.
15. Roses, D., Brooks, A., Hartus, M., Shapiro, R., Mintnick, J. Complications of Level I. and II. Axillary Dissection in the Treatment of Carcinoma of the Brest. Ann. Surg., 1999, 230, 194–201.
16. Silverstein, M., Skinner, K., Lomis, T. Predicting Axillary Nodal Positivity in 2282 Patients With Breast Carcinoma. World J. Surg., 2001, 25, 767–772.
17. Moore, M., Kinne, D. Axillary Lymphadenectomy: A Diagnostic and Therapeutic Procedure. J. Surg. Oncol., 1997, 66, 2–6.
18. Weaver, D., Krag, D., Manna, E. Detection of occult sentinel lymph node micrometastases by irnunohistochernistry in breast cancer an NSABP Protocol B-32 Quality assurance study. Cancer, 2006, 107, 661–667.
19. Roumen, R., Kuijt, G., Liem, I., Beek, M. Treatment of 100 patients with sentinel node-negative breast cancer without further axillary dissection. Br. J. Surg., 2002, 88, 1639–1643.
20. Guiliano, A., Haigh, P., Brennan, et al. Prospective Observational Study of Sentinel Lymphadenectomy Without Further Axillary Dissection in Patients With Sentinel Node – Negative Breast Cancer. J. Surg. Oncol., 2000, 18, 2553–2559.
21. Chun, M., Steinhoff, M., Cady, B. Clinical axillary recurrence in breast cancer patients after negative sentinel node biopsy. Am. J. Surg., 2002, 184, 310–314.
22. Chung, M., Steinhoff, M., Cady B. Clinical axillary reccurence in breast cancer patients after a negative sentinel node biopsy Am. J. Surg., 2002, 184, 310–314.
23. McMasters, K., Giuliano, A., Ross, M., Reintgen, D., Hunt, K., Byrd, D., Klimberk, S., Whitworth, P., Tafra, L., Edwards, M. Sentinel Lymph Node Biopsy for Breast Cancer-Not Yet the Standard of Care. N. Engl. J. Med., 1998, 339, 990–994.
24. Borgstein, P., Meijer, S., Pijpers, R., Diest, P. Functional Lymphatic Anatomy for Sentinel Node Biopsy in Breast Cancer. Ann. Surg., 2000, 232, 81–89.
25. Klimberg, S., Rubio, I., Henry, R., Cowan, Ch., Korourian, S. SubareolarVersus Peritumoral Injection for Location of the Sentinel Lymph Node. Ann. Surg., 1999, 229, 860–865.
26. Shen, P.,Glass, E., DiFironzo Dermal versus intraparenchmal Lymphoscintigraphy of the breast. Ann. Surg. Oncology, 2001, 8, 241–248.
27. Borgstein, P., Meijer, S, Pijpers, R. Intradermal blue dye to identify sentinel lymphnode in breast cancer. Lancet, 1997, 349, 1668–1669.
28. Smith, L., Cross, M., Klimberg, V. Subareolar Injection Is a Better Technique for Sentinel Lymph Node Biopsy. Am. J. Surg., 2000, 180, 434–438.
29. McMasters, K., Wong, S., Martin, R., et al. Dermal Injection of Radioactive Colloids Is Superior to Peritumoral Injection for Breast Cancer Sentinel Lymph Node Biopsy: Results of a Multiinstitutional Study. Ann. Surg., 2001, 233, 676–687.
30. Cody, H., Fey, J. Akhurst, T, et al. Complementary of Blue Dye and Isotope in Sentinel Node Localization for Breast Cancer: Univariate and Multivariate Analyslsis of 966 Procedures. Ann. Surg. Oncol., 2001, 8, 13–19.
31. Burak, W., Michael, J., Walker, J. Routine Preoperative Lymphoscintigraphy Is Not Necessary Prior to Sentinel Node Biopsy for Breast Cancer. Am. J. Surg., 1999, 177, 445–449.
32. McMasters, K., Wong, S., Tuttle, T., et al. Preoperative Lymphoscintigraphy for Breast Cancer Does Not Improve the Ability to Identify Axillary Sentinel Lymph Nodes. Ann. Surg., 2000, 231, 724–731.
33. Borgstein, P., Pijpers, R., Comans, E., et al. Sentinel Lymph Node Biopsy in Breast Cancer: Guidelines and Pitfalls of Lymphoscintigraphy and Gamma Probe Detection. J. Am. Coll. Surg., 1998, 186, 275–283.
34. Noguchi, M. Sentinel lymph node biopsy and breast cancer. Br. J. Surg., 2002, 89, 21–34.
35. Nieweg, O. Lymphatic of the breast and the rationale for different injection techniques Ann. Surgical. Oncol., 2001, 8, 71–73.
36. Nos, C., MacKean, C., Fréneaux, P., et al. Prediction of tumor involvement in remaining axillary lymph nodes when the sentinel node in a woman with breast cancer contains metastases. Br. J. Surg., 2003, 90, 1354–1360.
37. Schrenk, P., Konstantiniuk, P., Wolfi, S., et al. Prediction of non-sentinel lymph node status in breast cancer with a micromestatic sentinel node. Br. J. Surg., 2005, 92, 707–713.
38. Turner, R., Ollila, D., Stern, S., Giuliano, A. Optimal Histopatologic examination of the sentinel lymph node for breast carcinoma staging. Am. J. Surg. Patol., 1999, 2, 263–267.
39. Motomura, K., Komoike, Y., Inaji, H., et al. Multiple sectioning and immunohistochemical staining of sentinel nodes in patiens with breast cancer. Br. J. Surg., 2002, 89, 1032–1034.
40. Liang, W., Sickle-Santanello, B., Nims, T. Is a completion axillary dissection indicated for micrometastases in the sentinel lymph node? Am. J. Surg., 2001, 182, 365–368.
41. Wong, S., Chao, C., Edwards, M., Simpson, D., McMasters, K. The use of cytokeratin staining in sentinel node biopsy for breast cancer. Am. J. Surg., 2001, 182, 330–334.
42. Teng, S., Dupont, E., McCann, Ch., Wang, J., Bolano, M., Durand, K., Peltz, E., et al. Do Cytokeratin -Positive - Only Sentinel Lymph Nodes Warrant Complete Axillary Lymph Node Dissection in Patients With Invasive Breast Cancer? Am. Surg., 2000, 66, 574–578.
43. Jakub, J., Diaz, N., Ebert, M., et al. Completion axillary lymph node dissection minimizes the likelihood of false negatives for patients with invasive breast carcinoma and cytokeratin positive only sentinel lymph nodes. Am. J. Surg., 2002, 184, 302–306.
44. Noguchi, M. Therapeutic relevance of brast cancer micrometastases in sentinel lymph nodes. Br. J. Surg., 2002, 89, 1505–1515.
45. Hill, A., Tran, K., Akhurst, T., et al. Lessons Learned from 500 Cases of Lymphatic Mapping for Breast Cancer. Ann. Surg., 1999, 229, 528–535.
46. Cody, H., Hill, D., Tran, K., Brennan, M., Borgen, P. Credentialing for Breast Lymphatic Mapping: How Many Cases Are Enough? Ann. Surg. 1999, 229, 723–728.
47. Siddharth, S. B., Cox, Ch., Ku, N., et al. The Role of Sentinel Lymph Node Biopsy in Breast Cancer. J. Am. Coll. Surg., 1999, 189, 183–194.
48. Albo, D., Wayne, J., Hunt, K., et al. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am. J. Surg., 2001, 182, 393–398.
49. Miner, T., Shriver, C., Jaques, D., et al. Sentinel Lymph Node Biopsy for Breast Cancer The Role of Previous Biopsy on Patient Eligibity. Am. Surg., 1999, 65, 493–499.
50. Cody, H. One-step surgery for breast cancer: Back to the future? World J. Surg., 2007, 31, 1153–1154.
51. Giuliano, A., Daniel, M. K., Guenther, J., Morton, D. L. Lymphatic Mapping and Sentinel Lymphadenectomy for Breast Cancer. Ann. Surg., 1994, 220, 391–401.
52. Krag, D., Weaver, D., Ashigaka ,T., Klimberk, S., et al. The Sentinel Node in Breast Cancer. N. Eng. J. Med., 1998, 339, 941–946.
53. Siddharth, S. B., Cox, Ch., Ku, N., et al. The Role of Sentinel Lymph Node Biopsy in Breast Cancer. J. Am. Coll. Surg., 1999, 189, 183–194.
54. McMasters, K., Wong, S., Chao, C., et al. Defining the Optimal Surgeon Experience for Breast Cancer Sentinel Lymph Node Biopsy: A Model for Implementation of New Surgical Techniques. Ann. Surg., 2001, 234, 292–300.
55. Tafra, L., Lanin, D., Swanson, M., et al. Multicenter Trial of Sentinel Node Biopsy for Breast Cancer using Both Technetium Sulfur Colloid and Isosulfan Blue Dye. Ann. Surg., 2001, 233, 51–59.
56. Tafra, L. The learning curve and sentinel node biopsy. Am. J. Surg., 2001, 182, 347–350.
57. Bergkvist, J., Frisell, J., Liljegren, G., et al. Multicentre study of detection and falše negative rates in sentinel node biopsy for breast cancer. Br. J. Surg., 2001, 88, 1644–1648.
58. Červinka, V., Šťastný, K., Havlíček, K., Vyhnálková, I., Vaňásek, J., Pavlíková, E., Rothrockel, P., Hácová, M., Nechvátal, L. Naše zkušenosti s detekcí sentinelové uzliny. Rozhl. Chir., 2004, roč. 83, č. 6., s. 217–220.
59. Hruška, J. Biopsie sentinelové uzliny na našem pracovišti. Rozhl. Chir., 2002, 81, č. 4, s. 170–171.
60. Pavlišta, D., Dudorkinová, D., Novotný, J. K problematice vyšetření sentinelových lymfatických uzlin u karcinomu prsu. Čes. Gynek., 2005, roč. 70, č. 3, s. 197–200.
61. Strnad, P., Rob, L., Zuntová, A., Chod, J., Halaška, M. Biopsie sentinelové lymfatické uzliny u karcinomu prsu v praxi. Čes. Gynek., 2005, roč.70, č.4, s. 291–295.
62. Gatěk, J., Bakala, J., Dudešek, B., Duben, J., Hnátek, L., Dvořáčková, J. Biopsie sentinelové uzliny v chirurgické léčbě karcinomu prsu: prospektivní studie Čes. Gynek., 2003, 68, č. l, s. 6–10.
63. Gatěk, J., Duben, J., Dudešek, B., Haša, E., Adámek, M. Sentinelová uzlina u karcinomu prsu. Rozhl. Chir., 2000, 79, č. 2, s. 77–80.
64. Vážan, P., Velecký, J., Gatěk, J. Vyšetření sentinelových uzlin u karcinomu prsu pomocí rychlé peroperační biopsie a imunohistochemie v sériových řezech. Čes.-slov. Patol., 43, 2007, 43, č. l, s. 13–17.
Labels
Surgery Orthopaedics Trauma surgeryArticle was published in
Perspectives in Surgery
2008 Issue 4
Most read in this issue
- Patient Quality of Life Following Resection Procedures for Chronic Pancreatitis
- Experience With Ventral Hernioplasties According to Chevrel With „On-lay“ Prolene Mesh
- Chronic pancreatitis, Indications for Resection Procedures and Postoperative Complications
- Our Experience with Pancreatic Resection Procedures. Retrospective Analysis